Takeda Pharmaceutical Co. Ltd.
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed February 13, 2025), Takeda Pharmaceutical Co. Ltd. reported 13 stock positions worth $232.3 million. Its top holding was Denali Therapeutics (DNLI) at 42.1% of the portfolio, followed by Hillevax (HLVX, 41.9%) and Phathom Pharmaceuticals (PHAT, 6.9%). Compared with Q1 2024, it sold out of 2 and reduced 3. The biggest sale was Phathom Pharmaceuticals (PHAT, shares −51%).
- Most Recent 13F
- Q3 2025
- Location
- Tokyo, M0
- CIK
- 0001395064
- Portfolio Value
- $232.3M (Q2 2024)
- SEC Filing
- 0001395064-25-000028 ↗ filed Feb 13, 2025
Holdings Value
Holdings 13 stocks · $232.3M
| DNLI Denali Therapeutics Inc. | 42.13% | 4,214,559 | $97.9M | No change |
| HLVX Hillevax Inc. | 41.85% | 6,724,000 | $97.2M | No change |
| PHAT Phathom Pharmaceuticals Inc. | 6.90% | 1,557,063 | $16.0M | Reduce -50.6% |
| WVE Wave Life Sciences Ltd. | 2.89% | 1,346,892 | $6.7M | No change |
| OVID Ovid Therapeutics Inc. | 2.49% | 7,531,996 | $5.8M | No change |
| TSBX Turnstone Biologics Corp. | 1.01% | 895,824 | $2.3M | No change |
| STTK Shattuck Labs Inc. | 0.86% | 515,619 | $2.0M | Reduce -65.7% |
| XLO Xilio Therapeutics Inc. | 0.60% | 1,475,121 | $1.4M | No change |
| EQ Equillium Inc. | 0.54% | 1,824,977 | $1.3M | No change |
| RANI Rani Therapeutics Holdings Class A | 0.35% | 215,172 | $818K | Reduce -36.5% |
| AMWL American Well Corp. Class A | 0.22% | 1,554,669 | $505K | No change |
| AKLI Akili Inc. | 0.14% | 738,819 | $321K | No change |
| LAB Standard Biotools Inc. | 0.01% | 16,515 | $29K | No change |
Portfolio Sells Q1 2024 → Q2 2024
| PHAT Phathom Pharmaceuticals Inc. | Reduce -50.6% | 6.90% | −4.68 |
| STTK Shattuck Labs Inc. | Reduce -65.7% | 0.86% | −3.79 |
| DAWN Day One Biopharmaceuticals I | Sold out | 0.00% | −0.49 |
| AEROVATE THERAPEUTICS INC | Sold out | 0.00% | −0.14 |
| RANI Rani Therapeutics Holdings Class A | Reduce -36.5% | 0.35% | −0.01 |
Portfolio Buys Q1 2024 → Q2 2024
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q3 2025 | 8 | $16.4M | OVID, EQ, XLO, STTK, LYEL |
| Q2 2025 | 11 | $19.6M | HLVX, OVID, XLO, AMWL, EQ |
| Q1 2025 | 11 | $16.2M | HLVX, OVID, XLO, EQ, AMWL |
| Q4 2024 | 11 | $26.6M | HLVX, OVID, XLO, EQ, STTK |
| Q3 2024 | 10 | $38.0M | HLVX, WVE, OVID, STTK, EQ |
| Q2 2024 | 13 | $232.3M | DNLI, HLVX, PHAT, WVE, OVID |
| Q1 2024 | 15 | $289.0M | HLVX, DNLI, PHAT, OVID, STTK |